TROPION-Lung01 Study Design and Baseline demographics
Raludotatug deruxtecan (R-DXd; DS-6000) monotherapy in patients
with previously treated ovarian cancer (OVC): subgroup analysis of
a first-in-human Phase 1 study
Kathleen Moore, 1,2 Alexander Philipovskiy,2,3 Kenichi Harano, 4 Brian Rini, 5 Kazuki Sudo, Shigehisa Kitano, David R. Spigel, 2,8 Jie Lin, Madan G. Kundu,⁹ Amine
Bensmaine, 10 Yusuke Myobatake,⁹ Erika Hamilton 2,8
1Oklahoma University, Oklahoma City, OK, USA; 2Sarah Cannon Research Institute, Nashville, TN, USA; ³Florida Cancer Specialists, Lake Mary, FL, USA; 4National Cancer Center Hospital East, Kashiwa, Japan; "Vanderbilt-
Ingram Cancer Center, Nashville, TN, USA; National Cancer Center Hospital, Tokyo, Japan; 7Japanese Foundation for Cancer Research, Tokyo, Japan; 8Tennessee Oncology, PLLC, Nashville, TN, USA; Daiichi Sankyo, Inc.,
Basking Ridge, NJ, USA; 10Daiichi Sankyo, Inc., Rueil-Malmaison, France.
Daiichi-Sankyo
52
62View entire presentation